Human Papillomavirus (HPV) Associated Cancer – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Human Papillomavirus (HPV) Associated Cancer – Pipeline Review, H2 2017’, provides an overview of the Human Papillomavirus (HPV) Associated Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Human Papillomavirus (HPV) Associated Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Human Papillomavirus (HPV) Associated Cancer

The report reviews pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Human Papillomavirus (HPV) Associated Cancer therapeutics and enlists all their major and minor projects

The report assesses Human Papillomavirus (HPV) Associated Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Human Papillomavirus (HPV) Associated Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Human Papillomavirus (HPV) Associated Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Human Papillomavirus (HPV) Associated Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Abion Inc

Admedus Ltd

Advaxis Inc

Amgen Inc

Antigen Express Inc

Astex Pharmaceuticals Inc

Atara Biotherapeutics Inc

Bionor Pharma AS

BioNTech AG

Cancer Research Technology Ltd

Denceptor Therapeutics Ltd

Etubics Corp

EyeGene Inc

Formune SL

Genexine Inc

Hookipa Biotech AG

iBio Inc

Immunovaccine Inc

Inovio Pharmaceuticals Inc

Iovance Biotherapeutics Inc

ISA Pharmaceuticals BV

Johnson & Johnson

Juno Therapeutics Inc

Karyopharm Therapeutics Inc

Kite Pharma Inc

MedImmune LLC

Merck KGaA

NeoImmuneTech Inc

Onconova Therapeutics Inc

Oryx GmbH & Co KG

PDS Biotechnology Corp

Peregrine Pharmaceuticals Inc

Profectus BioSciences Inc

Rottapharm Biotech Srl

Selecta Biosciences Inc

Shantha Biotechnics Pvt Ltd

Shuttle Pharmaceuticals LLC

Sirnaomics Inc

Theravectys SA

THEVAX Genetics Vaccine USA Inc

Transgene SA

UbiVac LLC

Vaccibody AS

Vault Pharma Inc

Virometix AG

VLPbio

Vyriad Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Human Papillomavirus (HPV) Associated Cancer - Overview 6

Human Papillomavirus (HPV) Associated Cancer - Therapeutics Development 7

Human Papillomavirus (HPV) Associated Cancer - Therapeutics Assessment 19

Human Papillomavirus (HPV) Associated Cancer - Companies Involved in Therapeutics Development 27

Human Papillomavirus (HPV) Associated Cancer - Drug Profiles 49

Human Papillomavirus (HPV) Associated Cancer - Dormant Projects 230

Human Papillomavirus (HPV) Associated Cancer - Discontinued Products 232

Human Papillomavirus (HPV) Associated Cancer - Product Development Milestones 233

Appendix 244

List of Tables

List of Tables

Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Abion Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Admedus Ltd, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Advaxis Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Amgen Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Antigen Express Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Astex Pharmaceuticals Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Atara Biotherapeutics Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Bionor Pharma AS, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by BioNTech AG, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Cancer Research Technology Ltd, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Denceptor Therapeutics Ltd, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Etubics Corp, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by EyeGene Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Formune SL, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Genexine Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Hookipa Biotech AG, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by iBio Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Immunovaccine Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Inovio Pharmaceuticals Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Iovance Biotherapeutics Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by ISA Pharmaceuticals BV, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Johnson & Johnson, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Juno Therapeutics Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Karyopharm Therapeutics Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Kite Pharma Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by MedImmune LLC, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Merck KGaA, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by NeoImmuneTech Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Onconova Therapeutics Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Oryx GmbH & Co KG, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by PDS Biotechnology Corp, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Peregrine Pharmaceuticals Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Profectus BioSciences Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Rottapharm Biotech Srl, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Selecta Biosciences Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Shantha Biotechnics Pvt Ltd, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Shuttle Pharmaceuticals LLC, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Sirnaomics Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Theravectys SA, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by THEVAX Genetics Vaccine USA Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Transgene SA, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by UbiVac LLC, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Vaccibody AS, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Vault Pharma Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Virometix AG, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by VLPbio, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Pipeline by Vyriad Inc, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Dormant Projects, H2 2017

Human Papillomavirus (HPV) Associated Cancer – Dormant Projects, H2 2017 (Contd..1), H2 2017

Human Papillomavirus (HPV) Associated Cancer – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Human Papillomavirus (HPV) Associated Cancer, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports